5 terminated, 2 completed, 2 withdrawn. 9 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Terminated 5, Completed 2, Withdrawn 2 |
| Phase 1 | 3 | Terminated 2, Withdrawn 1 |
Follow Celularity Incorporated: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma CYNK-101, Pembrolizumab, Trastuzumab - Metastatic HER2 Positive Gastroesophageal Junction Cancer | Phase 1 / Phase 2 | Terminated | Celularity Incorporated | 1 | 2022-04-14 | 2024-12-12 |
| CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type CYNK-001 systemic and Intra cavity administration - Astrocytoma, Grade IV, Glioblastoma | Phase 1 / Phase 2 | Withdrawn | Celularity Incorporated | 2021-09-01 | 2026-06-08 | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 CYNK-001 - Coronavirus, Coronavirus Infection | Phase 1 / Phase 2 | Terminated | Celularity Incorporated | 7 | 2020-09-02 | 2026-06-26 |
| A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy PDA-002, Placebo - Diabetic Nephropathies, Peripheral Nervous System Diseases | Phase 2 | Completed | Celularity Incorporated | 26 | 2015-10-27 | 2022-02-02 |
| Hemodynamic Effects of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease PDA-002, Placebo - Diabetic Foot, Peripheral Arterial Disease | Phase 2 | Withdrawn | Celularity Incorporated | 2015-06-01 | 2026-04-29 | |
| Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD. PDA-002, Placebo - Peripheral Arterial Disease, Diabetic Foot | Phase 2 | Terminated | Celularity Incorporated | 159 | 2014-10-23 | 2026-06-12 |
| Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic Stroke Human Placenta-Derived Cells PDA001- (cenplacel-L), Placebo - Stroke, Acute, Middle Cerebral Artery Stroke | Phase 2 | Terminated | Celularity Incorporated | 44 | 2011-03-01 | 2018-03-01 |
| Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis PDA001, Vehicle Controlled Placebo - Rheumatoid Arthritis | Phase 2 | Terminated | Celularity Incorporated | 26 | 2010-12-01 | 2020-07-22 |
| PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease Human Placenta-Derived Cells PDA001 Intravenous Infusion, Vehicle Control - Crohn's Disease | Phase 2 | Completed | Celularity Incorporated | 50 | 2010-08-01 | 2026-07-07 |
Diabetic Foot (2) · Peripheral Arterial Disease (2) · Arthritis, Rheumatoid (1) · COVID-19 (1) · Coronaviridae Infections (1) · Coronavirus Infections (1) · Crohn Disease (1) · Diabetic Nephropathies (1) · Glioblastoma (1) · Immune System Diseases (1) · Infarction, Middle Cerebral Artery (1) · Infarction, Posterior Cerebral Artery (1) · Lung Diseases (1) · Nidovirales Infections (1) · Peripheral Nervous System Diseases (1)
Cyclophosphamide (1) · Mesna (1) · Trastuzumab (1) · aldesleukin (1) · fludarabine (1) · fludarabine phosphate (1) · pembrolizumab (1)
United States (8)
Adrian Kilcoyne, MD (1) · Corey Casper, MD MPH (1) · Monica E Luchi, MD (1) · Sharmila Koppisetti (1) · Sharmila Koppisetti, MD (1) · Solveig Ericson, MD (1)